Health Technology Assessment (HTA)

Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.

Cracks through the ice on a melting glacier in Alaska
News

OHE at HESG: Value-based Assessment in the UK; Developing the EQ-5D-5L

23 January 2014

OHE’s contributions focused on approaches to implementing UK value-based assessment and the details of creating an EQ-5D-5L value set for England. The Health Economists’ Study Group…

2014 Opportunity New
Publication

Opportunity Costs of Implementing NICE Decisions in NHS Wales

1 June 2014

This new research from the OHE examines how Local Health Boards (LHBs) in Wales adjust spending to meet the statutory requirement of providing access to technologies…

Cracks through the ice on a melting glacier in Alaska
Publication

The Expanding Value Footprint of Oncology Treatments

1 May 2014

This report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. Included are the ten cancer drugs approved by the EMA during 2003–2005. Decisions by France’s HAS, NICE and Aetna in the US are analysed.

396 - 2014 Role-of-HTA-for-Biosimilars-Mestre-Ferrandiz-Jul2015
Publication

What is the Role of HTA for Biosimilars?

1 April 2014

This Briefing summarises the results of a roundtable convened by OHE to discuss using HTA to assess biosimilars – including which methods are most appropriate in…

395 - 2014 Can-the-US-Afford-Chambers-2014-BIG
Publication

Can the US Afford to Ignore Cost-effectiveness Evidence?

1 March 2014

Cost-effectiveness analysis plays a limited role in US health care compared to many other countries. In this Seminar Briefing, Dr James Chambers, Center for the Evaluation…

Cracks through the ice on a melting glacier in Alaska
News

Inconsistent Use of Cost-effectiveness Thresholds in NHS Scotland

12 December 2013

This study finds an apparent mismatch in the decision making approaches of the SMC and the NHS Boards. OHE today released a Research Paper on the…

Cracks through the ice on a melting glacier in Alaska
News

Using MCDA to Assess the Value of Treatments for Rare Diseases

5 December 2013

A pilot study demonstrated the value of involving a range of stakeholders in MCDA for rare disease therapies. According to a study just published by the…

OHE's Health Outcomes Group
News

OHE Consulting Offers New Services in Patient-Reported Outcomes

4 December 2013

OHE Consulting is now offering our clients advice and analytical services on health outcomes and the use of patient-reported outcomes (PRO) data, building on the extensive…

Cracks through the ice on a melting glacier in Alaska
News

Mike Herdman Appointed as OHE’s Head of Health Outcomes

25 November 2013

OHE’s extensive expertise in health outcomes will be further enhanced with the addition of Mike. OHE is delighted to announce the appointment of Mike Herdman as…